News stories about Depomed (NASDAQ:DEPO) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Depomed earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 43.8223876520572 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

Shares of Depomed (NASDAQ:DEPO) traded up 2.67% during midday trading on Wednesday, hitting $5.39. The stock had a trading volume of 1,064,282 shares. The stock’s market capitalization is $339.51 million. Depomed has a 52 week low of $4.93 and a 52 week high of $24.09. The stock has a 50 day moving average price of $5.91 and a 200-day moving average price of $9.12.

Depomed (NASDAQ:DEPO) last posted its quarterly earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.09 by ($0.52). Depomed had a negative return on equity of 45.03% and a negative net margin of 26.02%. The company had revenue of $100.00 million during the quarter, compared to the consensus estimate of $100.40 million. During the same quarter in the prior year, the business earned $0.27 earnings per share. The firm’s revenue for the quarter was down 14.3% on a year-over-year basis. Equities research analysts anticipate that Depomed will post $0.46 earnings per share for the current year.

DEPO has been the topic of a number of research reports. BidaskClub downgraded Depomed from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Royal Bank Of Canada set a $13.00 price objective on Depomed and gave the stock a “hold” rating in a research note on Sunday, July 16th. Janney Montgomery Scott downgraded Depomed from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $18.00 to $8.00 in a research note on Tuesday, August 8th. Morgan Stanley downgraded Depomed from an “equal weight” rating to an “underweight” rating and dropped their price objective for the stock from $12.00 to $5.00 in a research note on Tuesday, August 8th. Finally, Piper Jaffray Companies reissued a “neutral” rating and issued a $9.00 price objective (down previously from $10.00) on shares of Depomed in a research note on Wednesday, August 9th. Four analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $12.94.

ILLEGAL ACTIVITY WARNING: “Depomed (DEPO) Receives Daily News Impact Score of 0.06” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/10/18/depomed-depo-receives-daily-news-impact-score-of-0-06.html.

About Depomed

Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).

Insider Buying and Selling by Quarter for Depomed (NASDAQ:DEPO)

Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.